Iconovo AB

Iconovo attends DCAT in New York this week meeting customers and partners. Exploring the interest in intranasal anti-obesity treatments and in substitutable generic Ellipta products - our ICOpre project.

Iconovo receives a grant of SEK 670,000 from Innowwide to target the Japanese market We are pleased to announce that Iconovo has received a grant from Innowwide to support our expansion into the Japanese market. This funding will help us further establish our presence in collaboration with our local representative, Zinagi. We look forward to strengthening our footprint in Japan and advancing our global reach. "Last year, we carried out a similar project in South Korea with great success and now we are moving forward with Japan to further increase our presence in the important Asian markets. Our interactions with Japanese companies have generated great interest and significant potential for the development of inhaled drugs, and the grant from Innowwide gives us the opportunity to, in a structured way, establish ourselves in one of the world's largest pharmaceutical markets," says Johan Wäborg, CEO of Iconovo. Innowwide is part of the European Partnership for Innovative Small and Medium-sized Enterprises (SMEs) and is funded by the EU. Find the link to full press release in the comments

Iconovo released the full-year report for 2024 today. "Progress for ICOres budesonide/formoterol. Thus, we are following our plan to launch an interchangeable product for Symbicort" says Johan Wäborg, CEO Iconovo. To read the full report, find the link in comments.

GSK has announced impressive full-year 2024 sales figures for its three major Ellipta products: Relvar/Breo, Trelegy, and Anoro, totaling USD 5.4 billion with a growth rate of +17% (CER). This marks a significant opportunity for Iconovo's substitutable ICOpre product.

Meet Iconovo at DCAT Week in New York March 17-20

Wegovy (semaglutide for obesity) by Novo Nordisk has demonstrated remarkable growth in Q4-2024, soaring by 107% to achieve sales of DKK 19.9 billion (USD 2.8 billion) in Q4. This impressive performance translates to an annual run rate exceeding USD 10 billion. Imagine if Wegovy could be administered via inhalation instead of injection? This is the bold vision of Iconovo! https://lnkd.in/da9uHv4S

Good news for patients with type 2 diabetes and chronic kidney disease. FDA approved the use of #injectable #semaglutide in these patients. #Injectable #semaglutide has now showed a reduction in cardiovascular disease and chronic kidney disease in patients with T2 diabetes. And the use is supported by FDA. But what if semaglutide could be #inhaled, rather than #injected? That's what Iconovo is aiming for with our intranasal semaglutide project. https://lnkd.in/dztTwycx

Injectable GLP-1 is currently making waves across medical circles, heralding a revolution in treating diabetes, obesity, and various metabolic diseases. But ouch! Another injection looms. What if a simple breath was all it took? That's why Iconovo is pioneering an intranasal GLP-1 alternative to injections. For those interested in systemic therapy of biologics via inhalation, consider listening to the presentation by Iconovo's senior scientific advisor, delivered in Copenhagen last year. https://lnkd.in/dM_Q2M_v

BIOSTOCK is covering the news that Iconovo and Lonza signed an agreement to collaborate on the formulation development of an intranasal biologic for the treatment of obesity. It gives more context regarding how it fits into Iconovo's strategy (Article in Swedish only). https://lnkd.in/dTJFRqXh

Iconovo and Lonza to collaborate on the formulation development of an intranasal biologic Iconovo announced that Iconovo and Lonza has initiated a collaboration to develop spray-dried formulations of an intranasal biologic for Iconovo’s proprietary intranasal device ICOone Nasal. This project, with a reformulated substance for obesity, is the first in Iconovo’s strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation. https://lnkd.in/dHuaSGQy